sglt2 Archives - BCDiabetes

BC Pharmacare to cover SGLT-2 inhibitors and to delist the Lantus brand of insulin glargine U100

Dr. Tom Elliott — Tue, 28 May 2019 17:30:22 +0000

Yesterday BC Minister of Health Adrian Dix announced Pharmacare coverage of the SGLT-2 inhibitor class represented by empagliflozin (Jardiance). Although BCDiabetes would have preferred that all three SGLT2 inhibitors on the Canadian market be covered, the long overdue announcement was most welcome news. Our readers will be aware of the long-running BCDiabetes advocacy campaign for […]

The post BC Pharmacare to cover SGLT-2 inhibitors and to delist the Lantus brand of insulin glargine U100 appeared first on BCDiabetes.

Third SGLT2 inhibitor to be marketed in Canada

Dr. Tom Elliott — Mon, 05 Oct 2015 17:08:05 +0000

Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada. Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine. This results in increased urine volumes in all patients and a tripling […]

The post Third SGLT2 inhibitor to be marketed in Canada appeared first on BCDiabetes.

U.S. FDA warns on SGLT2 inhibitors, a class of type 2 diabetes drugs

Dr. Tom Elliott — Wed, 20 May 2015 13:52:22 +0000

This past Friday the US Federal Drug Administration released a warning that some newer type 2 diabetes drugs, known as SGLT2 inhibitors, may cause ketoacidosis, or dangerously high levels of blood acids that could require hospitalization. The warning comes from the US, but what does this mean for Canada. Our Medical Director, Dr. Tom Elliott, lets us know. […]

The post U.S. FDA warns on SGLT2 inhibitors, a class of type 2 diabetes drugs appeared first on BCDiabetes.